 | | Vol. 12.27 – 13 July, 2021 |
| |
|
|
| Researchers generated tissue-specific “loss-” and “gain-of-function” models for endothelial nitric oxide synthase (eNOS) by using cell-specific Cre-induced gene inactivation or reactivation.
[Circulation] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| HSCs that lacked melanoma differentiation-associated protein 5 (MDA5) exhibited an impaired inflammatory response after chemotherapy and retained their quiescence, with consequent better long-term repopulation capacity.
[Nature Cell Biology] |
|
|
|
| Expression of YBX1 was significantly upregulated in myeloid leukemia cells, and deletion of YBX1 dramatically induced apoptosis and promoted differentiation coupled with reduced proliferation and impaired leukemic capacity of primary human and mouse acute myeloid leukemia cells in vitro and in vivo.
[Blood] |
|
|
|
| Scientists examined the effects of a rapamycin pretreatment of epithelial cell adhesion molecule (EpCAM) chimeric antigen receptor (CAR)-T cells and assessed the in vivo antitumor efficacy of rapamycin pretreated EpCAM CAR-T cells and CD33 CAR-T cells in leukemia xenograft mouse models.
[Clinical Cancer Research] |
|
|
|
| Using a murine chronic myeloid leukemia (CML) model, investigators examined leukemia-induced alterations in mesenchymal cell populations and showed that 6C3+ stromal progenitors expanded in CML bone marrow and exhibited increased leukemia stem cells but reduced HSC supportive capacity.
[Cell Reports] |
|
|
|
| Infusions of bone marrow-derived macrophages exposed to high glucose increased hematopoiesis, circulating myeloid cell numbers, and atherosclerotic lesions with an accumulation of macrophage foam and apoptotic cells.
[iScience] |
|
|
|
| The authors studied the gene expression and function in systemic-onset juvenile idiopathic arthritis to assess the biological role of CD71+ erythroid cells in systemic inflammation.
[Scientific Reports] |
| |
|
|
| Researchers compared long-term outcomes of 106 patients having T cell mixed chimerism after day 60 and undergoing allogeneic stem cell allograft for acute leukemia from an unrelated donor, with 111 patients having complete chimerism.
[Blood Cancer Journal] |
|
|
|
| Scientists analyzed the outcome of 65 patients reported to the registry of the European Working Group of myelodysplastic syndrome in childhood carrying a germline GATA2 mutation who had undergone HSC transplantation.
[Bone Marrow Transplantation] |
|
|
|
| Untreated older acute myeloid leukemia (AML) patients were randomized to cytarabine and daunorubicin followed by cytarabine consolidation with or without G3139. Addition of G3139 to chemotherapy failed to improve outcomes of older AML patients.
[Blood Advances] |
|
|
|
| In this first study reporting results with recombinant factor IX Fc fusion protein (rFIXFc) in pediatric previously untreated patients (PUPs) with hemophilia B, rFIXFc was well tolerated, with the adverse event profile as expected in a pediatric hemophilia population.
[Blood Advances] |
|
|
|
|
| Advances in genomic sequencing, increased understanding of hemoglobin regulation and discoveries of molecular tools for genome modification of HSCs have made gene therapy for sickle cell disease possible. These therapies need to be portable, safe and efficient to make an in vivo based approach attractive.
[Blood] |
|
|
|
| Therapeutic strategies such as splicing modulators to correct splicing-related defects and targeting differentiation of early erythroid progenitors to increase the erythroid output in myelodysplastic syndrome (MDS) provide new avenues to target MDS symptoms untreatable previously.
[Trends in Molecular Medicine] |
|
|
|
|
| Vor Biopharma, a cell therapy company pioneering engineered HSC therapies combined with targeted therapies for the treatment of cancer, announced the formation of a collaboration with Janssen Biotech, Inc.
[Vor Biopharma] |
|
|
|
| Trillium Therapeutics, Inc. announced that it has dosed the first acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine and venetoclax.
[Trillium Therapeutics, Inc.] |
|
|
|
| INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase I clinical trial of its Natural Killer cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome.
[INmune Bio, Inc.] |
|
|
|
|
| August 25 – 28, 2021
Virtual |
|
|
|
|
|
| | Karolinska Institutet – Flemingsberg, Sweden |
|
|
|
| | The Technical University of Munich – Munich, Germany |
|
|
|
| | Georg-Speyer-Haus – Frankfurt, Germany |
|
|
|
| | The Westmead Institute for Medical Research – Sydney, Australia |
|
|
|
| | Heinrich Heine University Düsseldorf – Düsseldorf, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
